3D optical/CT and PET validation of blood brain barrier opening by high intensity focused ultrasound treatment for intra-cerebral delivery of therapeutics
Conclusions: Multimodality 3D optical/CT and PET are valid translational methods to confirm drug delivery through a permeabilized BBB that can be used to enhance drug development in a preclinical setting. Furthermore, PET scanning using radiolabeled therapeutics has the potential to be translated to humans, as HIFU-mediated BBB permeability has entered early stage clinical trials. Support: NIH/NCI 5P01CA207206. The PET early drug development program is supported by the Columbia Dept. of Radiology and Irving Institute CTSA Translational Therapeutics Accelerator (UL1TR001873).
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Molotkov, A., Bhatt, N., Doubrovin, M., Solingapuram Sai, K. K., Mintz, A. Tags: Novel Nonradioactive Probes (Poster Session) Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Clinical Trials | High Intensity Focused Ultrasound Therapy | Neurology | Nuclear Medicine | PET Scan | Radiology | Study | Ultrasound